US 12,240,848 B2
Azaindole rock inhibitors
Thomas Maxwell Kaiser, Charleston, SC (US)
Assigned to Avicenna Biosciences, Inc., Durham, NC (US)
Filed by Avicenna Biosciences, Inc., Durham, NC (US)
Filed on Mar. 19, 2024, as Appl. No. 18/610,051.
Application 18/610,051 is a continuation of application No. PCT/US2023/086402, filed on Dec. 29, 2023.
Claims priority of provisional application 63/436,408, filed on Dec. 30, 2022.
Prior Publication US 2024/0254124 A1, Aug. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/4045 (2006.01); A61K 31/437 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/4045 (2013.01); A61K 31/437 (2013.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01)] 13 Claims
 
1. A compound of structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.